<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A159BFCD-0A2C-4BC3-9CEA-573ACE508A6F"><gtr:id>A159BFCD-0A2C-4BC3-9CEA-573ACE508A6F</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>McElnay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13075"><gtr:id>34C1AA56-E1EC-4EE0-BDD6-15BB18F45B4E</gtr:id><gtr:title>Queens University Belfast Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13075</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14300</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Hyaluronic acid microneedles: In-skin swelling behaviour</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>L'Oreal (Paris)</gtr:fundingOrg><gtr:id>7E7F00F8-D9D5-4632-833E-D9D8A473445F</gtr:id><gtr:outcomeId>58c91dcca0eab5.76238344</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of EGFR-targeted camptothecin-loaded nanoparticles for targeting Kras wild-type colorectal cancer</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5ACE95AB-A1F9-4067-9F61-BBFBBA2502A8</gtr:id><gtr:outcomeId>54637399a53cf5.80572837</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Nano-formulations for Sustained Intraocular Drug Delivery</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:id>5474E9A0-1747-4CCE-BAA0-E88709925E6C</gtr:id><gtr:outcomeId>58c91e4f93a5d5.79629020</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle-mediated Intraocular Delivery of Bevacizumab using Semifluorinated Alkanes</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Novaliq GmbH</gtr:fundingOrg><gtr:id>A7179AF4-06A4-4D6B-AF32-B4638C3A4B66</gtr:id><gtr:outcomeId>58c91f0cdcded8.79822370</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>383387</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Elucidate the mechanisms underpinning direct reprogramming of endothelial cells for use in regenerative medicine</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A5568480-8CF6-41CF-A6BF-21ABC10ABBA1</gtr:id><gtr:outcomeId>56e16da9182520.78978624</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The utility of MN as a dosage form capable of reducing methotrexate side effects in children</gtr:description><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>7EF534BC-39FA-4D64-AB7B-35F161934DF0</gtr:id><gtr:outcomeId>56e15d5f513625.11694808</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Defining the therapeutic potential of cathepsin S in CF lung disease</gtr:description><gtr:fundingOrg>Cystic Fibrosis Foundation</gtr:fundingOrg><gtr:id>9973FFEB-2605-4B5B-BBC9-BCA4ADFCDE96</gtr:id><gtr:outcomeId>56e16cfd6fda39.01044361</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104760</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Transdermal delivery of fixed-dose drug combinations enabled by novel second generation microneedle arrays</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:id>366466E2-C512-42D7-A308-9E685077CAE0</gtr:id><gtr:outcomeId>58c91d2b920293.21079116</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine resiues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell del ivery system comprising the amph ipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules.</gtr:description><gtr:grantRef>MC_PC_13075</gtr:grantRef><gtr:id>25756E3F-E547-4FBF-AFC5-E329FF218726</gtr:id><gtr:impact>The patent progressed to PCT and was published under WO2014087023, the patent was nationalised and is pending in the US and Europe. The technology has also been combined with WO2009040548 to achieve even greater effectiveness of delivery for vaccines.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c9164a81b101.06976031</gtr:outcomeId><gtr:patentId>WO2014087023</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>AN AMPHIPATHIC PEPTIDE</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.</gtr:description><gtr:grantRef>MC_PC_13075</gtr:grantRef><gtr:id>02FE73AA-FB40-493E-82B1-70403545687F</gtr:id><gtr:impact>The patent is now granted in the US, published under US9110163 B2 on 18 August 2015, and China, published under CN102428370B on 25/04/2012 and is pending in Europe. This project has informed the development of the FKBPL biomarker as a companion diagnostic for ALM201 and directly contributed to the filing of a US patent continuation on 16 July 2015 which includes methods to stratify patients response to ALM201 using the biomarker.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c91598e32c42.77120610</gtr:outcomeId><gtr:patentId>WO2010133880</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A priority patent application has being filed entitled 'ocular compositions' relating to the formulation and use of ocular compositions that can be administered to the eye in various forms to achieve controlled release of a therapeutic agent (or drug). We are in the process of drafting a PCT application. The technology including the patent is exclusively licensed to Revana Ocular Ltd, a QUB spin out company.</gtr:description><gtr:grantRef>MC_PC_13075</gtr:grantRef><gtr:id>6EDFA213-13EE-406A-AAFF-5BF405A4AC42</gtr:id><gtr:impact>The technology including the patent is exclusively licensed to Revana Ocular Ltd, a QUB spin out company.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c916b29ace37.93134798</gtr:outcomeId><gtr:protection>Patent application published</gtr:protection><gtr:title>Development and Preclinical Evaluation of Novel Long-acting Injectable Ocular Implants</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>713A4641-47A6-4FE0-BBA1-55259206A22F</gtr:id><gtr:title>Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb5e167f9c4f242f6847ebad194f200e"><gtr:id>fb5e167f9c4f242f6847ebad194f200e</gtr:id><gtr:otherNames>Schmid D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58c919eb7bbd49.73170016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10392629-7E98-46AD-8887-383842F14BCF</gtr:id><gtr:title>Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19764cfdb8374428fa7eb1cc7343b89f"><gtr:id>19764cfdb8374428fa7eb1cc7343b89f</gtr:id><gtr:otherNames>McCarthy HO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>58c919836f20b3.73562383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20657A54-20B3-4339-968E-10244AE8B751</gtr:id><gtr:title>P102 Development of a Novel Assay for the Detection of Active Neutrophil Elastase in Patients with Chronic Obstructive Pulmonary Disease</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6deee7018abf971b4f8d7f821a17ffc0"><gtr:id>6deee7018abf971b4f8d7f821a17ffc0</gtr:id><gtr:otherNames>Moffitt K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58c91bfb3d2419.17858309</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13075</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>